AbbVie Inc (ABBV)vsEnbridge Inc (ENB)
ABBV
AbbVie Inc
$201.55
-0.57%
HEALTHCARE · Cap: $358.55B
ENB
Enbridge Inc
$53.59
-0.74%
ENERGY · Cap: $116.95B
Smart Verdict
WallStSmart Research — data-driven comparison
Enbridge Inc generates 4% more annual revenue ($65.19B vs $62.82B). ENB leads profitability with a 11.5% profit margin vs 5.8%. ABBV appears more attractively valued with a PEG of 0.57. ENB earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
ENB
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-19.7%
Fair Value
$168.33
Current Price
$201.55
$33.22 premium
Margin of Safety
+4.6%
Fair Value
$54.02
Current Price
$53.59
$0.43 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 31.6%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Earnings expanding 294.9% YoY
Conservative balance sheet, low leverage
Large-cap with strong market position
Reasonable price relative to book value
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 45.8%
Distress zone — elevated risk
Weak financial health signals
Expensive relative to growth rate
Negative free cash flow — burning cash
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.57 suggests the stock is reasonably priced for its growth.
Bull Case : ENB
The strongest argument for ENB centers on EPS Growth, Debt/Equity, Market Cap.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 98.9x leaves little room for execution misses.
Bear Case : ENB
The primary concerns for ENB are Piotroski F-Score, PEG Ratio, Free Cash Flow.
Key Dynamics to Monitor
ENB carries more volatility with a beta of 0.79 — expect wider price swings.
ABBV is growing revenue faster at 12.4% — sustainability is the question.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (63/100 vs 63/100) and 12.4% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Enbridge Inc
ENERGY · OIL & GAS MIDSTREAM · USA
Enbridge Inc. is an energy infrastructure company. The company is headquartered in Calgary, Canada.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?